ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Base-editor-focused Beam brings in more cash

by Lisa M. Jarvis
March 9, 2019 | APPEARED IN VOLUME 97, ISSUE 10

Beam Therapeutics has raked in $135 million in its second formal financing round. Since launching in May 2018, the biotech firm has raised over $220 million to develop therapies that use base-editing technology from David R. Liu’s lab at Broad Institute of MIT and Harvard. These next-generation gene-editing tools allow researchers to make single-nucleotide base changes in DNA, an approach that could offer a fix for the swath of genetic diseases driven by an error in a single letter. Beam says it will use the funds to expand its team and move programs toward the clinic.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment